Minerva Neurosciences, Inc (NERV) Dividend History

Company News

• Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight

  The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.

  GlobeNewswire Inc.

  Featured Companies: RVPH
• Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

  Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.

  Zacks Investment Research

  Featured Companies: ALXO RNAC
• Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod

  Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.

  Zacks Investment Research

  Featured Companies: ALXO SRPT
• Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

  Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.

  Zacks Investment Research

  Featured Companies: ALXO BMY LGND
• Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

  Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.

  Zacks Investment Research

  Featured Companies: ALXO LGND